Finally, the authors also looked at expression of SGLT2 on human non–small cell lung cancer biopsy specimens from patients treated with programmed death protein-1 (PD-1) and found increased progression-free and overall survival in patients whose biopsies displayed >50% SGLT2 expression, suggesting that SGLT2 expression may predict clinical response to immunotherapy. This evidence concerns the gene SLC5A2 and lung cancer.